WO2003057874A1 - Disease markers for renal diseaes and utilization thereof - Google Patents

Disease markers for renal diseaes and utilization thereof Download PDF

Info

Publication number
WO2003057874A1
WO2003057874A1 PCT/JP2002/013777 JP0213777W WO03057874A1 WO 2003057874 A1 WO2003057874 A1 WO 2003057874A1 JP 0213777 W JP0213777 W JP 0213777W WO 03057874 A1 WO03057874 A1 WO 03057874A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
disease
renal
glomerular fibrosis
polynucleotides
disease markers
Prior art date
Application number
PCT/JP2002/013777
Other languages
French (fr)
Inventor
Eiji Sugaru
Junji Ichihara
Mutsuo Taiji
Original Assignee
Sumitomo Pharmaceuticals Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/01Hexosyltransferases (2.4.1)
    • C12Y204/0108Ceramide glucosyltransferase (2.4.1.80)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Abstract

Disease markers reflecting renal diseases accompanied by glomerular fibrosis; a method of detecting a renal disease accompanied by glomerular fibrosis using such a disease marker; and a method of screening a drug useful in ameliorating these disease. Namely, polynucleotides having at least 15 consecutive bases in the base sequence of ceramide glucosyltransferase (CGT) gene and/or polynucleotides complementary to these polynucleotides, etc. are used as disease markers for renal diseases accompanied by glomerular fibrosis. A drug for ameliorating renal diseases accompanied by glomerular fibrosis can be screened by bringing a test substance into contact with cells expressing the CGT gene and then examining the occurrence, increase or regulation of the expression of the CGT gene.
PCT/JP2002/013777 2001-12-28 2002-12-27 Disease markers for renal diseaes and utilization thereof WO2003057874A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2001-401076 2001-12-28
JP2001401076 2001-12-28

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003558172A JPWO2003057874A1 (en) 2001-12-28 2002-12-27 Disease markers and the use of renal disease

Publications (1)

Publication Number Publication Date
WO2003057874A1 true true WO2003057874A1 (en) 2003-07-17

Family

ID=19189720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/013777 WO2003057874A1 (en) 2001-12-28 2002-12-27 Disease markers for renal diseaes and utilization thereof

Country Status (2)

Country Link
JP (1) JPWO2003057874A1 (en)
WO (1) WO2003057874A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028241A1 (en) * 2004-09-08 2006-03-16 Takeda Pharmaceutical Company Limited Preventive/therapeutic drug for arteriosclerosis
JP2008519840A (en) * 2004-11-10 2008-06-12 ジェンザイム・コーポレイションGenzyme Corporation A method of treatment diabetes
WO2010014554A1 (en) * 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
JP2012504608A (en) * 2008-10-03 2012-02-23 ジェンザイム コーポレーション 2-acylamino-propanol - type glucosylceramide synthase inhibitor
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8716327B2 (en) 2006-05-09 2014-05-06 Genzyme Corporation Methods of treating fatty liver disease
US8912177B2 (en) 2007-10-05 2014-12-16 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
WO2017170610A1 (en) * 2016-03-29 2017-10-05 株式会社国際電気通信基礎技術研究所 Screening method for candidate substances for active component to prevent or treat at least one disease selected from the group consisting of renal hypofunction, chronic kidney disease and kidney failure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748868A2 (en) * 1995-06-15 1996-12-18 THE INSTITUTE OF PHYSICAL & CHEMICAL RESEARCH Ceramide glucosyltransferase
US6277574B1 (en) * 1999-04-09 2001-08-21 Incyte Genomics, Inc. Genes associated with diseases of the kidney
US6333408B1 (en) * 1999-03-08 2001-12-25 Kureha Chemical Industry Co., Ltd. Oligonucleotides inhibitors of PAI-1 MRNA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748868A2 (en) * 1995-06-15 1996-12-18 THE INSTITUTE OF PHYSICAL & CHEMICAL RESEARCH Ceramide glucosyltransferase
US6333408B1 (en) * 1999-03-08 2001-12-25 Kureha Chemical Industry Co., Ltd. Oligonucleotides inhibitors of PAI-1 MRNA
US6277574B1 (en) * 1999-04-09 2001-08-21 Incyte Genomics, Inc. Genes associated with diseases of the kidney

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KODAMA S. ET AL.: "Glycosyl ceramide synthesis in the developing spinal cord and kidney of the twitcher mouse an enzymatically authentic model of human krabbe disease", J. NEUROCHEM., vol. 39, no. 5, 1982, pages 1314 - 1381, XP002965255 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028241A1 (en) * 2004-09-08 2006-03-16 Takeda Pharmaceutical Company Limited Preventive/therapeutic drug for arteriosclerosis
US9532976B2 (en) 2004-11-10 2017-01-03 Genzyme Corporation Method of lowering blood glucose
JP2008519840A (en) * 2004-11-10 2008-06-12 ジェンザイム・コーポレイションGenzyme Corporation A method of treatment diabetes
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
US8716327B2 (en) 2006-05-09 2014-05-06 Genzyme Corporation Methods of treating fatty liver disease
US9556155B2 (en) 2006-05-09 2017-01-31 Genzyme Corporation Methods of treating fatty liver disease
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US9745294B2 (en) 2007-05-31 2017-08-29 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8940776B2 (en) 2007-05-31 2015-01-27 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8912177B2 (en) 2007-10-05 2014-12-16 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
JP2011529500A (en) * 2008-07-28 2011-12-08 ジェンザイム コーポレーション Glucosylceramide synthase inhibitors for the treatment of collapsing glomerulopathy and other glomerular diseases
WO2010014554A1 (en) * 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
JP2015131839A (en) * 2008-07-28 2015-07-23 ジェンザイム コーポレーション Glucosylceramide synthase inhibition for treatment of collapsing glomerulopathy and other glomerular disease
US9481671B2 (en) 2008-07-28 2016-11-01 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US8729075B2 (en) 2008-07-28 2014-05-20 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US9272996B2 (en) 2008-10-03 2016-03-01 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
JP2012504608A (en) * 2008-10-03 2012-02-23 ジェンザイム コーポレーション 2-acylamino-propanol - type glucosylceramide synthase inhibitor
US9744153B2 (en) 2008-10-03 2017-08-29 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
WO2017170610A1 (en) * 2016-03-29 2017-10-05 株式会社国際電気通信基礎技術研究所 Screening method for candidate substances for active component to prevent or treat at least one disease selected from the group consisting of renal hypofunction, chronic kidney disease and kidney failure

Also Published As

Publication number Publication date Type
JPWO2003057874A1 (en) 2005-05-19 application

Similar Documents

Publication Publication Date Title
Martin The Parkinson's puzzle
WO2005005622A3 (en) Method of altering cell properties by administering rna
CA2352451A1 (en) High throughput method for discovery of gene clusters
USD484809S1 (en) Bottle
Han et al. Postcranial anatomy of Jeholosaurus shangyuanensis (Dinosauria, Ornithischia) from the Lower Cretaceous Yixian Formation of China
EP1120056A3 (en) Shock-absorbing sole structure
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
WO2001070776A2 (en) Nimr compositions and their methods of use
WO2004080533B1 (en) Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue
USD475451S1 (en) Vitamin tablet
CA2548780A1 (en) Parts assembly and part for a prosthesis
WO2001036679A3 (en) METHODS FOR GENERATING SINGLE STRANDED cDNA FRAGMENTS
JPH03117489A (en) Riboflavin-overproducing strain of bacterium
WO2002099068A3 (en) LCES AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2002018587A1 (en) Process for producing biopterins
CA2348842A1 (en) Muco-adhesive polymers, use thereof and method for producing the same
USD484675S1 (en) Shoe upper
WO2003057874A1 (en) Disease markers for renal diseaes and utilization thereof
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
USD439198S1 (en) Composition of twisted springs
CA2214895A1 (en) Improved pharmaceutical composition comprising fenofibrate
USD414124S (en) Voltmeter
JPH0353893A (en) Preparation of lymphotoxin derivative
Fazio et al. [Preparation and characterization of protein materials from grapeseed meals].[Italian]
WO2004011611A3 (en) Taci antibodies and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003558172

Country of ref document: JP

122 Ep: pct application non-entry in european phase